JB Pharma, one of the fastest growing pharmaceutical companies in India, today, has announced that it has received final approval from USFDA for its Abbreviated New Drug Application (ANDA), Venlafaxine Extended Release Tablets 37.5 mg, 75 mg, 150 mg and 225 mg.

This product is based on OROS (Osmotic Controlled Release Oral Delivery System) technology, an advanced and precision controlled release mechanism – an area where JB has seen success with 3 products already in the US market. JB Pharma now has 17 US ANDA approvals.

The generic product approval is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Venlafaxine Hydrochloride Extended-Release Tablets, 37.5 mg, 75 mg, 150 mg, and 225 mg, of Osmotica Pharmaceutical U.S. LLC. A selective serotonin and norepinephrine reuptake inhibitor (SNRI), Venlafaxine Extended-Release tablets are indicated for major depressive disorder (MDD) and social anxiety disorder (SAD).

As per IQVIA Health MAT Oct 2022 data, Venlafaxine Extended-Release tablets recorded annualized sales of approximately $ 48 million in the US.

Commenting on the approval, Mr. Nikhil Chopra, CEO and Wholetime Director, JB Pharma said, “Venlafaxine extended release tablets will be our fourth offering in the US market based on advanced OROS (Osmotic controlled Release Oral delivery System) technology, which demonstrates JB Pharma’s ability to leverage and deliver quality products using its OROS platform and deliver high quality medicines to patients. We remain committed to expand our brand portfolio in structured and strategic way”.

About JB Pharma
J.B. Pharma, established in 1976, is one of the fastest growing pharmaceutical companies in India and a leading player in the hypertension segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has five brands among the top 300 IPM brands in the country. The company exports its finished formulations to over 40 countries including the USA. Besides supplying branded generic formulations to several countries, it is also a leader in the manufacturing of medicated lozenges. The company ranks among the top 5 manufacturers globally in medicated and herbal lozenges. It has seven state of the art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world.

For more details on J.B. Pharma, please visit www.jbpharma.com.

Media Contact
Dr. Swadeep Srivastava
Heal Health PR
Tel: +91 93100 87601
Email :drswadeep@hhconnect.in

Investor Contact
Mr. Sidharth Ragnekar / Ms. Shruti Joshi
CDR India
Tel : +91-98335 57572
Email : sidharth@cdr-india.com
Shruti@cdr-india.com

Report Abuse